Document:

Development, Manufacturing, and Supply Agreement

  
 Exhibit 10.20

 [*| Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 DEVELOPMENT, MANUFACTURING, AND
SUPPLY AGREEMENT 
 THIS DEVELOPMENT, MANUFACTURING,
AND SUPPLY AGREEMENT, together with exhibits attached hereto (the “Agreement”), effective as of March 27th, 2007 (the “Effective Date”), is
entered into by and between DIADEXUS, INC., organized under the laws of Delaware and having its principal place of business at 343 Oyster Point Boulevard, South San Francisco,
California 94080, United States of America (“diaDexus”), and DENKA SEIKEN, organized under the laws of Japan and having its principal place of business at 3-4-2 Nihonbashi
Kayabacho, Chuo-ku, Tokyo 103-0025, Japan (“Denka Seiken”). diaDexus and Denka Seiken may each be referred to herein individually as a “Party” or, collectively, as “Parties.” 

RECITALS 
 WHEREAS, diaDexus has technology and intellectual property related [*] 

WHEREAS, Denka Seiken is engaged in the business of developing, manufacturing, and supporting
diagnostic tests and related products; and 
 WHEREAS, diaDexus and Denka Seiken wish to
enter into an agreement under which Denka Seiken will manufacture and supply diaDexus or its designees with [*]
                             diagnostic test kits, as set forth in more detail herein, subject to the terms
and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the
promises and undertakings set forth in this Agreement, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 Capitalized terms not otherwise defined in this Agreement will have the meaning set forth below: 
 1.1    “Affiliates” means, with respect to either Party, any person or entity controlling, controlled by, or under common control with such Party. For the
purposes of this Section 1.1 only, “control” means (a) the possession, directly or indirectly, of the power to direct the management or policies of a person or entity, whether through the ownership of voting securities, by
contract, or otherwise, or (b) the ownership, directly or indirectly, of at least fifty percent (50%) of the voting securities or other ownership interest of a person or entity; provided that, if local law requires a minimum percentage of
local ownership in excess of fifty percent (50%), then control will be established by direct or indirect beneficial ownership of one hundred percent (100%) of the maximum ownership percentage that may, under such local law, be owned by foreign
interests. 
 1.2    “Certificate of Nonconformance” means a
certificate of analysis signed and dated by a person qualified and duly authorized by diaDexus to certify that the results of assays conducted on an indicated shipment of Products under this Agreement do not conform to the Specifications therefor
and indicating the reason(s) for nonconformance. The Certificate of Nonconformance shall include without limitation a description of the pertinent assay(s) conducted, the date on which it was (they were) conducted, and the results of the assay(s).

  
 1 

  

1.3    “Confidential Information” shall mean all data, technical or industrial
information, financial information, commercial information, trade secrets and know-how, which is disclosed or provided by either party (the “Disclosing Party”) to the other party (the “Receiving Party”), directly or indirectly,
and which if disclosed in writing is designated as confidential information in writing at the time of such disclosure or provision, or if disclosed orally is designated as confidential information in writing within thirty (30) days after such
disclosure. 
 1.4    “Control” means, with respect to any
information or an intellectual property right, possession of the ability, whether arising by ownership or license, to grant a license or sublicense to or under such information or right without violating the terms of any written agreement with any
Third Party. 
 1.5    “Critical Components” means those certain
materials specified in Exhibit 1.5. 
 1.6    “Denka Seiken
Technology” means the Denka Seiken Patent Rights and Denka Seiken Know-How, as defined below: 

(a)    “Denka Seiken Patent Rights” means any and all Patent Rights covering
the Denka Seiken Know-How necessary or useful solely for the development, manufacture and/or supply of Products by Denka Seiken, including but not limited to the patents and patent applications listed on Exhibit 1.6. 

(b)    “Denka Seiken Know-How” means the technology, information, expertise,
data, skills, processes, methods, know-how, trade secrets, and/or experience, including, without limitation, formulas and specifications, whether patentable or not, that are Controlled by Denka Seiken at anytime during the Term and are necessary or
useful solely for the development, manufacture, and/or supply of Products by Denka Seiken under this Agreement. 

1.7    “Denka Seiken Territory” means [*] 

1.8    “diaDexus Technology” means Intellectual property rights covering
Inventions, and the diaDexus Patent Rights and diaDexus Know-How, as defined below: 

(a)    “diaDexus Patent Rights” means any and all Patent Rights covering the
diaDexus Know-How necessary or useful solely for Denka Seiken to use the Critical Components in the development, manufacture and/or supply of Products under this Agreement, including but not limited to the patents and patent applications listed on
Exhibit 1.8. 
 (b)    “diaDexus Know-How” means the technology,
information, expertise, data, skills, processes, methods, know-how, trade secrets, and/or experience, including, without limitation, formulas and specifications, whether patentable or not, that are Controlled by diaDexus at anytime during the Term
and that are necessary or useful for Denka Seiken to use the Critical Components solely in the development, manufacture, and/or supply of Products under this Agreement. 

 
 [*] Certain information in this document has been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 2 

  

1.9    “FDA” means the U. S. Food and Drug Administration and any successor agency
thereto. 
 1.10    “Invention” shall mean any discovery, invention,
contribution, method, finding, or improvement, whether or not patentable, and all related know-how, that is conceived, reduced to practice, or otherwise developed by Denka Seiken, either solely or jointly with diaDexus, during the Term, or under the
Material Transfer Agreement dated November 1, 2005, that relates to diaDexus Technology, Critical Components, and/or Products. For the purpose of clarification, the term “Invention” shall include without limitation any and all
improved or modified versions of Critical Components and/or Products. 

1.11    “Lot” means a particular manufacturing run of Products. 

1.12    “Manufacturing Facility” means Denka Seiken’s [*]
                 facility located at [*] 
 1.13    “Patent Right” means: (i) all issued and existing patents, including any extensions, supplemental protection certificates, registrations, confirmations,
reissues, reexaminations, or renewals thereof; and (ii) all pending applications, including any provisional applications, converted provisional applications, continuing prosecution applications, and continuation, divisional, or
continuation-in-part applications thereof, for any of the foregoing. 

1.14    “Products” shall mean [*]
                     diagnostic test reagents and/or kits as further described in Exhibit 1.14, as may be amended from time to time in writing by the
Parties. 
 1.15    “Purchase Order” shall have the meaning assigned to it
in Section 2.7. 
 1.16    “Specification” means the written
specifications for a Product to be developed, manufactured, and supplied under this Agreement, as set forth in Exhibit 1.16, which may be modified from time to time in accordance with Section 2.3(b) or by mutual written agreement of the Parties
in accordance with this Agreement. For the purposes of clarification, the Specification shall be included in the definition of diaDexus Know-How. 
 1.17    “Term” shall have the meaning set forth in Section 9.1. 
 1.18    “Test” means a sufficient amount of Product to conduct an analysis of one sample [*] 

1.19    “Third Party” means any person or entity other than Denka Seiken, diaDexus,
or Affiliates of either. 
 1.20    “Transfer Price” shall mean with
respect to each Product, the price set forth in Section 3.3. 
  
 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

  
 3 

  

1.21    “Fiscal Year” shall mean each successive period of twelve months beginning
from April 1 ended March 31. 
 ARTICLE 2 

SUPPLY 
 2.1    Terms and Conditions. All supply of Products by Denka Seiken shall be subject to the terms and conditions of this Agreement. ANY TERMS OR CONDITIONS OF ANY PURCHASE ORDER
OR ACKNOWLEDGMENT GIVEN OR RECEIVED WHICH ARE ADDITIONAL TO OR INCONSISTENT WITH THIS AGREEMENT SHALL HAVE NO EFFECT AND SUCH TERMS AND CONDITIONS ARE HEREBY EXCLUDED AND REJECTED. 

2.2    Development. In partial consideration for the payments set forth in
Section 3.2, Denka Seiken shall perform any and all tasks reasonably necessary to prepare for supplying Products under this Agreement, including, without limitation, development, manufacturing and quality control documentation, training, travel
by Denka Seiken personnel to diaDexus necessary for technology transfer, and development of any and all necessary compliance documentation required by the FDA and the International Standards Organization (“ISO”). diaDexus shall
provide samples, reagents, and consultation necessary for the development of Products. Denka Seiken shall use its best efforts to complete the development of Products for commercialization in the shortest possible time. The development plan shall be
set forth and attached to this Agreement as Exhibit 2.2 (the “Development Plan”). Denka Seiken shall establish a development team, which shall work collaboratively and in consultation with diaDexus during the development of
Products. Denka Seiken shall appoint a representative of such development team who shall meet with a representative of diaDexus via teleconference no less than bimonthly to discuss the status of the development progress, including without limitation
any technical issues. Such teleconferences shall include a suitable translator, as necessary; such person to be Kevin Mangan or Yousuke Meguro, if available. Once a quarter, diaDexus may request such that meetings may be held face to face at
diaDexus. 
 2.3    Supply of Products and Development and Manufacturing
Information. 
 (a)    Supply. Denka Seiken shall supply Products to diaDexus as
set forth in this Article 2. 
 (b)    Specifications. All Products supplied pursuant
to Section 2.3(a) shall comply with all applicable Specifications. After the Effective Date, if diaDexus changes in writing the Specifications applicable to the product insert, labeling, or the addition of other languages thereon, then Denka
Seiken shall implement such changes; provided, however, that diaDexus shall pay Denka Seiken its actual cost, as demonstrated by invoices, to implement such changes, without any mark-up or other surcharges; provided, further, that Denka Seiken shall
notify diaDexus in advance and in writing of such costs and diaDexus’ obligation to reimburse Denka Seiken for such costs shall be subject to diaDexus’ approval, in its sole discretion, of such costs in writing before Denka Seiken incurs
any such costs. 

  
 4 

  

(c)    Denka Seiken shall provide diaDexus with all formulations, manufacturing procedures,
validation criteria, validation testing procedures, equivalence method tests, QC testing, and results as required for diaDexus to commercialize Product, including without limitation that required for customer needs, regulatory submissions, and
quality systems. 
 2.4    Good Manufacturing Practices. Denka Seiken shall
manufacture all Products under this Agreement in compliance with applicable current Good Manufacturing Practices and the Quality System Regulation for in vitro diagnostic devices, as set forth in 21 Code of Federal Regulations Part 820 et
seq., all applicable requirements of Directive 98/79/EC for obtaining CE Marking of such Products, and the In Vitro Diagnostics Directive (1VDD) ISO 13485:2003. All Products manufactured by Denka Seiken pursuant to a Purchase Order shall be
manufactured at and supplied from the Manufacturing Facility, and Denka Seiken shall not, without diaDexus’ prior written consent, manufacture Product at or supply Product from any facility other than the Manufacturing Facility. 

2.5    Forecasts. [*] 

diaDexus shall provide Denka Seiken with a written [*]
                        forecast (“Forecast”) of the quantities of each Product estimated by diaDexus to be
ordered from Denka Seiken under this Agreement [*]                     . The Forecast shall be updated by at least the [*]
                                         until
such time that both Parties agree that updating less frequently is acceptable; provided, however, that, notwithstanding the foregoing, an updated Forecast shall be provided [*]
                                     of the Term. The Parties agree
that the Forecast is nonbinding and shall be used (a) by Denka Seiken for its production planning purposes only and (b) for purposes of determining the Transfer Price to be paid to Denka Seiken pursuant to Section 3.3. 

2.6    Supply of Critical Components by diaDexus. [*]
                     after diaDexus files an application with the FDA for approval to sell Product in the United States, and subject to
Section 3.1, diaDexus shall supply Denka Seiken with a quantity of Critical Components that diaDexus, in its sole good faith estimation, believes will be sufficient to meet Denka Seiken’s needs under this Agreement [*]
                     manufacture of Products. Denka Seiken shall request additional supplies of Critical Components in writing from diaDexus [*]
                     before Denka Seiken reasonably anticipates that it will need such supplies to fulfill diaDexus’ orders for Products. Upon
receipt by Denka Seiken of Critical Components, Denka Seiken shall perform sufficient incoming quality control (“iQC”) procedures on such Critical Components to evaluate their suitability for use by Denka Seiken under this
Agreement. The Parties shall work together in good faith to agree on a protocol for such iQC standard operating procedures within sixty (60) days after the Effective Date, which procedures shall be set forth and attached to this Agreement as
Exhibit 2.6 (the “Critical Components SOP”). Denka Seiken shall notify diaDexus in writing of any deficiencies or defects in such Critical Components (the “iQC Notice”), including, without limitation, a detailed
description of such deficiencies or defects and the identity of the specific Critical Components with such deficiencies or defects. At diaDexus’ request, Denka Seiken shall at its expense return such Critical Components to diaDexus within three
(3) days after receiving such request. diaDexus shall have the right to replace such Critical Components to the extent it agrees that a deficiency or defect exists. If diaDexus disagrees with Denka Seiken that such deficiency or defect exists,
the Parties shall cooperate in good faith to evaluate such Critical Components and agree on whether they are acceptable for use by Denka Seiken under this Agreement. If diaDexus fails to receive an iQC Notice within thirty (30) days after Denka
Seiken’s receipt of Critical Components, then such Critical Components shall be conclusively deemed acceptable for use by Denka Seiken in the manufacture of Products under this Agreement, and Denka Seiken shall have no recourse or other remedy
against diaDexus arising from any failure, deficiency, or defect, of any kind or nature, relating to such Critical Components. Denka Seiken shall use any and all such Critical Components solely in the manufacture by Denka Seiken of Products under
this Agreement, and shall keep written records of the amounts used for each Lot. diaDexus shall have the right to audit Denka Seiken’s use of Critical Components supplied under this Agreement. 

 
 [*] Certain information in this document has been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 5 

 2.7    Purchase Orders. diaDexus shall use the
standard form of purchase order set forth in Exhibit 2.7 to request the manufacture of Products under this Agreement for delivery to diaDexus by Denka Seiken (“Purchase Order”). During the Term, diaDexus shall have the right to
place a firm Purchase Order with Denka Seiken for Products, setting forth the quantity of tests to be manufactured by Denka Seiken during a specified period. Denka Seiken shall accept any and all such Purchase Orders from diaDexus; provided,
however, that if Denka Seiken has insufficient Critical Components in inventory pursuant to Section 2.6 to fulfill such entire Purchase Order, Denka Seiken shall only be obligated to fulfill that portion for which it has sufficient Critical
Components. Denka Seiken shall use its best efforts to fulfill all Purchase Orders within sixty (60) days after receipt by Denka Seiken, but in no event later than ninety (90) days after such receipt, unless the Purchase Order received
from diaDexus expressly sets forth in writing a later completion date, in which event Denka Seiken shall fulfill the Purchase Order on such later date. Denka Seiken shall notify diaDexus in writing within seven (7) days after receipt of a
Purchase Order if Denka Seiken will be unable to fill any amount(s) of such Purchase Order, provided that such notice will not waive any of the supply obligations of Denka Seiken under this Agreement. All shipments shall be in compliance with
Section 2.10, and will include information related to Denka Seiken’s handling charges, direct shipping costs, and Lot number tracking. 
 2.8    Product Inspection. 

(a)    Product Release Criteria. At the sole discretion of diaDexus, within ten (10) days
after a Lot is ready for testing, Denka Seiken shall either (i) test each such Lot for compliance with any and all applicable Specifications or (ii) provide to diaDexus Tests from each Lot in a quantity sufficient, in diaDexus’ sole
good faith discretion, for diaDexus to test and qualify the Products. If Denka Seiken is the Party testing a Lot, (A) the cost of the Products used by Denka Seiken for its testing shall be borne by Denka Seiken and (B) Denka Seiken shall
promptly provide diaDexus in writing any and all such test results and data (the “Test Results”) and, at diaDexus’ request, Products from such Lot shall be provided to diaDexus for the purpose of verifying such Test Results.

 (b)    Replacement Product. If either Denka Seiken or diaDexus determines,
pursuant to Section 2.7, that a Lot or Product does not comply with all of the applicable Specifications including Product release criteria and shelf life, then Denka Seiken shall replace such Lot or Product at no cost or expense to diaDexus.
As between the Parties, diaDexus’ sole remedy for claims referred to in this Section 2.8 shall in no event exceed such replacement cost. 

  
 6 

  

(c)    Labeling. Denka Seiken shall clearly label, in accordance with Section 4.1(a)(iii)
and the Specifications, each Product for supply hereunder with a unique Lot number, part number, description of contents, shelf life, bar coding, multi-language label (if applicable), and other identifying information, as applicable. 

(d)    Inspection of Denka Seiken Facilities. diaDexus shall have the right, at reasonable
times during normal business hours and upon request made upon reasonable prior notice to Denka Seiken, to inspect the Manufacturing Facility and any facilities used for storing the Products for diaDexus, and Denka Seiken’s batch records,
work-in-progress, raw materials, production, and storage records for the Products supplied to diaDexus under this Agreement. Denka Seiken shall cooperate in good faith with all requests for inspection or information from the FDA. 

(e)    Technical Contacts. Within thirty (30) days after the Effective Date, each Party
shall notify the other Party in writing of the names, telephone numbers, fax numbers, and e-mail addresses of at least one person to serve as the Party’s technical contact under this Agreement and at least one person to serve as the
Party’s business contact under this Agreement. A Party may change its business or technical contacts at any time with written notice to the other Party. 
 2.9    Product Warranties. Denka Seiken warrants that the Products supplied by Denka Seiken hereunder will: (i) conform to the applicable Specifications including shelf
life at the time of shipment of the Products by Denka Seiken; and (ii) be free of any manufacturing defects. Denka Seiken further represents and warrants that title to all Products supplied by Denka Seiken hereunder shall pass to diaDexus free
and clear of all security interests, liens, and other encumbrances. 
 2.10    Shipment;
Handling Fees. All Products delivered pursuant to the terms of this Agreement shall be suitably packed for shipment by Denka Seiken in accordance with the applicable Specifications, marked for shipment to diaDexus, and shipped [*]
                                        . Such
packing, and the manner of shipment, shall be sufficient to prevent damage, contamination, or degradation during shipment and during unpacking at the destination. All freight, insurance, and other shipping expenses from the point of shipment shall
be borne [*]                     . The carrier shall be selected by diaDexus. Denka Seiken shall use all reasonable commercial efforts to ship
quantities of Product for delivery on the dates specified in the applicable Purchase Order. 
  
 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

  
 7 

  

2.11    Inspection and Rejection. 

(a)    Nonconforming Shipments. If within thirty (30) days after receipt of a shipment of
Product, diaDexus finds that the Product does not comply with the applicable Specifications in effect at the time of shipment, diaDexus shall provide Denka Seiken with a Certificate of Nonconformance for said shipment, such Certificate of
Nonconformance to include a written statement specifying the nature and basis for the claim. diaDexus shall also return such nonconforming Product in accordance with Denka Seiken’s reasonable instructions, at Denka Seiken’s expense;
provided that diaDexus may retain a reasonable sample thereof solely for further testing. Denka Seiken shall cooperate to solve such a claim in good faith as quickly as possible. 

(b)    Third Party Verification. If, within a period of thirty (30) days after Denka
Seiken’s receipt of a Certificate of Nonconformance, Denka Seiken is unable to verify that the applicable Product failed to conform to the Specifications at the time of original delivery by Denka Seiken to the carrier, then the matter shall be
submitted to and be finally decided by a nationally recognized independent testing laboratory if requested by either Party; provided, however, that if Denka Seiken has, at its sole cost and expense, replaced such Product with Product acceptable to
diaDexus, then no such independent laboratory testing under this Section 2.11 (b) and Section 2.1 l(c) shall be required unless diaDexus determines, at its sole good faith discretion, that there is a trend of Products that fail or do
not comply with the applicable Specifications. This laboratory shall be selected by Denka Seiken and approved in writing by diaDexus, such approval not to be unreasonably withheld and not to be delayed more than ten (10) days, if not otherwise
agreed in writing by both Parties within five (5) days of either Party’s request. 

(c)    Third Party Testing. diaDexus shall send a sample of the nonconforming shipment and a
copy of the Certificate of Nonconformance to such testing laboratory within ten (10) days after either Party’s written request. Such testing laboratory shall be requested by the Parties to complete its testing and to render its written
decision, supported by its description of procedures and basis for its findings within thirty (30) days after being engaged to perform said testing. Each Party, at its own expense, shall reasonably assist and cooperate with such laboratory in
performing such testing by making available such documentation, facilities, reagents, and other materials as the laboratory may request of the Party. The Parties agree that the written decision of such testing laboratory shall be accepted as final
and binding. In case the laboratory test proves that the relevant Product did not comply with the Specifications at the time of delivery by Denka Seiken to the carrier, then all cost and expense of transportation, shipping, insurance, and the like
related to the testing shall be paid by Denka Seiken. 
 (d)    Credit or Refund. In
the event that Product supplied by Denka Seiken under the terms of this Agreement is determined to be nonconforming Product, Denka Seiken shall reimburse diaDexus for the full purchase price paid to Denka Seiken, if any, for such nonconforming
Product. 
 2.12    Product Support, 

(a)    Support. 

(i)    diaDexus and its distributors of Products shall provide first-call direct customer
support and product complaint handling for all Products under this Agreement, subject to this Section 2.12. 

  
 8 

  

(ii)    If diaDexus and its distributors are unable to provide sufficient support pursuant to
Section 2.12(a)(i) because the product complaint or customer support issue falls within the technical expertise of Denka Seiken, Denka Seiken, at its expense and at the request of diaDexus, shall assist diaDexus with any such product complaint
or customer support issue. Denka Seiken shall dedicate sufficient personnel to provide the support set forth in this Section 2.12(a), including answering calls from diaDexus. For messages received from diaDexus during nonworking hours at Denka
Seiken, Denka Seiken shall contact diaDexus as soon as possible on the next day that Denka Seiken resumes work, but in no event more than two (2) business days after Denka Seiken resumes work. 

2.13    Invoicing. 

(a)    diaDexus shall submit invoices to Denka Seiken for Critical Components, including
shipping and handling charges pursuant to Section 2.10. diaDexus shall send all invoices to Denka Seiken’s address for notices hereunder or such other address as designated by Denka Seiken in writing. The invoice shall separately itemize
any insurance, taxes, handling fees, or other costs incident to the transfer(s) or shipment(s) initially paid by diaDexus but to be borne by Denka Seiken pursuant to this Agreement. 

(b)    Denka Seiken shall submit invoices for Products, including shipping and handling
charges pursuant to Section 2.10, to diaDexus for Products produced for sale pursuant to a Purchase Order no earlier than the date that diaDexus receives from Denka Seiken such Products. Denka Seiken shall send all invoices to diaDexus’
address for notices hereunder or such other address as designated by diaDexus in writing, and each such invoice shall state the aggregate and applicable unit Transfer Prices, pursuant to Section 3.3, for the Products invoiced. The invoice shall
separately itemize any insurance, taxes, handling fees, or other costs incident to the transfer(s) or shipment(s) initially paid by Denka Seiken but to be borne by diaDexus pursuant to this Agreement. 

ARTICLE 3 

PAYMENTS 
 3.1    Payment for Critical Components. Subject to this Section 3.1, Denka Seiken shall pay to diaDexus [*]
                                    . diaDexus, in its sole
discretion, may change the price of Critical Components; provided, however, that any such change in price of Critical Components shall be reflected by an equal change in the Transfer Prices set forth in Section 3.3. [*] 

 
 [*] Certain information in this document has been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 9 

  
 [*] 

3.2    [*] 

(a)    [*] 

(b)    [*] 

3.3    Transfer Price. For all Products ordered via Purchase Orders, diaDexus shall pay to
Denka Seiken the Transfer Price for all such Products shipped by Denka Seiken under this Agreement, as set forth in the table below, unless modified in accordance with Section 3.1. 

[*] 
  

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 10 

  
 [*] 

Notwithstanding the end of the Fiscal Year adjustment described above, diaDexus shall make full payment to Denka Seiken for all Products,
including Transfer Prices pursuant to this Section 3.3 and handling fees or other costs to be paid by diaDexus pursuant to Section 2.10, within thirty (30) days after diaDexus receives an undisputed invoice from Denka Seiken pursuant
to Section 2.l3(b). 
 Diadexus and Denka Seiken shall negotiate in good faith reasonable commercial compensation for the
Critical Components and a transfer price for the controls and calibrators described in Exhibit 1.14. 
 diaDexus shall consider
in good faith volume-wise discount for the Critical Components in a similar scheme stipulated for the Transfer Price for Products based on scale and cost of the production of the Critical Components. 

3.4    Mode of Payment. All payments shall be made by check or direct wire transfer of U.S.
Dollars in immediately available funds in the requisite amount to such bank account as the receiving Party may from time to time designate by written notice to the other Party. 

3.5    Late Payment. Any payments or portions thereof due under this Agreement that are not
paid when due shall bear interest equal to the lesser of the prime rate as reported by the Chase Manhattan Bank, New York, New York, on the date such payment is due, plus an additional two percent (2%), or the maximum rate permitted by law if lower,
calculated based on the number of days after a Party provides the other Party with written notice that the payment is past due. This Section 3.5 shall in no way limit any other remedies available to either Party. 

ARTICLE 4 

LICENSES 
 4.1    Grant to Denka Seiken. 

(a)    Research and Manufacturing License. Subject to the terms and conditions of this
Agreement, diaDexus hereby grants to Denka Seiken, during the Term, a non-exclusive license [*] , without the right to grant sublicense rights: 
 (i)    under the diaDexus Technology, solely to make and use Products, for the purpose of developing Products exclusively on behalf of diaDexus under this Agreement; 

 
 [*] Certain information in this document has been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 11 

  

(ii)    under the diaDexus Technology, solely to make Products, for the purpose of supplying
Products exclusively to diaDexus, or to a customer or designee of diaDexus, under this Agreement; and 

(iii)    under the diaDexus Trademarks, to label Product solely upon the request of diaDexus;
provided that all representations of diaDexus Trademarks that Denka Seiken intends to use if not previously approved by diaDexus as provided in this Section 4.1(a)(iii), will first be submitted to diaDexus for approval, such approval not to be
unreasonably withheld. 
 (b)    [*] 

4.2    Grant to diaDexus. Subject to the terms and conditions of this Agreement, Denka Seiken
hereby grants to diaDexus: 
 (a)    an exclusive, worldwide [*]
                                        
perpetual license, with the right to grant sublicense rights, under the Denka Seiken Technology, solely to use, sell, offer for sale, and import Products. 
 (b)    [*] 

4.3    [*] 

4.4    [*] 

 
 [*] Certain information in this document has been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 12 

  
 [*] 

4.5    No Other Rights. Except for the rights expressly granted under this Agreement,
no right, title, or interest of any nature whatsoever is granted by either Party to the other Party. diaDexus and Denka Seiken retain all rights, exclusively and worldwide, [*] 
 ARTICLE 5 
 INTELLECTUAL PROPERTY
RIGHTS 
 5.1    Ownership. As between the Parties, subject only
to the licenses set forth in Section 4.1, diaDexus shall retain all right, title, and interest in and to the diaDexus Technology and Products. Denka Seiken shall promptly provide written notice to diaDexus of any and all Inventions. [*]

 5.2    Patent Rights Prosecution and Maintenance. 

(a)    diaDexus, at diaDexus’ expense, shall have the right, but not the obligation, to
control the prosecution and maintenance of the diaDexus Patent Rights. 

(b)    diaDexus shall control the prosecution and maintenance of any patents and patent
applications claiming or covering any Inventions worldwide. [*] 
 Each Party will copy the other Party on
correspondence associated with the Invention from any patent office. Each Party will cooperate, in all reasonable ways, in connection with the prosecution of all such patent applications and maintenance of all such patents. Denka Seiken shall make
available to diaDexus or its authorized attorneys, agents, or representatives such of its employees or consultants as Denka Seiken in its reasonable judgment deems necessary in order to assist diaDexus with the prosecution and maintenance of such
patents. diaDexus shall make available to Denka Seiken or its authorized attorneys, agents, or representatives such of its employees or consultants as diaDexus in its reasonable judgment deems necessary in order to assist Denka Seiken with the
prosecution and maintenance of such patents. 
  
 [*]
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 13 

  

5.3    Enforcement. 

(a)    At any time during the Term, if a Party determines that a Third Party is or may be
infringing any patent, or may have misappropriated any other right, within the diaDexus Technology or the Denka Seiken Technology, the Party making such determination shall promptly provide written notice to the other Party thereof. 

(b)    diaDexus, at diaDexus’ expense, shall have the right, but not the obligation, to
enforce all of the rights in the diaDexus Technology. 
 (c)    Denka Seiken, at
Denka Seiken’ expense, shall have the right, but not the obligation, to enforce all of the rights in the Denka Seiken Technology. 
 (d)    In the event that diaDexus enforces a right pursuant to this Section 5.3, Denka Seiken and its Affiliates, if applicable and wherever possible, shall cooperate fully
with diaDexus in such enforcement, including without limitation by joining as a party plaintiff and executing such documents as diaDexus may reasonably request. 

(e)    In the event that Denka Seiken enforces a right pursuant to this Section 5.3,
diaDexus and its Affiliates, if applicable and wherever possible, shall cooperate fully with Denka Seiken in such enforcement, including without limitation by joining as a party plaintiff and executing such documents as Denka Seiken may reasonably
request. 
 5.4    Allocation of Recovery. 

(a)    Any recovery awarded by a court of competent jurisdiction or final resort in an
unreversed, unappealed, or unappealable decision or judgment from an action by diaDexus to enforce any right within the diaDexus Technology shall be first applied to reimburse diaDexus’ unreimbursed expenses, and then Denka Seiken’s
unreimbursed expenses, including without limitation reasonable attorney’s fees and court costs. Any remaining amount of such damages or other monetary awards shall then be applied between the Parties in such action or proceeding on a pro rata
basis based upon such Parties’ respective out-of-pocket expenses directly associated with such action or proceeding. 
 (b)    Any recovery awarded by a court of competent jurisdiction or final resort in an unreversed, unappealed, or unappealable decision or judgment from an action by Denka
Seiken to enforce any right within the Denka Seiken Technology shall be first applied to reimburse Denka Seiken’ unreimbursed expenses, and then diaDexus’s unreimbursed expenses, including without limitation reasonable attorney’s fees
and court costs. Any remaining amount of such damages or other monetary awards shall then be applied between the Parties in such action or proceeding on a pro rata basis based upon such Parties’ respective out-of-pocket expenses directly
associated with such action or proceeding. 

  
 14 

  
 ARTICLE 6

 CONFIDENTIALITY 

6.1    Confidentiality Obligations. Each Party agrees that, for the Term and for five
(5) years thereafter, such Party will keep, and will ensure that its officers, directors, employees, and agents keep, strictly confidential and will not publish or otherwise disclose and will not use for any purpose except as permitted under
this Agreement any Confidential Information furnished to it by the other Party pursuant to this Agreement (including, without limitation, know-how of the disclosing Party); provided that, if any such Confidential Information is disclosed orally, the
disclosing Party shall provide the receiving Party a written summary of such Confidential Information within thirty (30) days after such initial oral disclosure. The foregoing confidentiality obligations will not apply to any information to the
extent that it can be established by such receiving Party that such information: 

(a)    was already known to the receiving Party as evidenced by its written records, other
than under an obligation of confidentiality, at the time of disclosure; 
 (b)    was
generally available to the public or was otherwise part of the public domain at the time of its disclosure to the receiving Party; 
 (c)    became generally available to the public or otherwise becomes part of the public domain after its disclosure and other than through any act or omission of the receiving
Party in breach of this Agreement; 
 (d)    was subsequently lawfully disclosed to
the receiving Party by a Third Party other than in contravention of a confidentiality obligation of such Third Party to the disclosing Party; or 
 (e)    was developed or discovered by employees of the receiving Party or its affiliates who had no access to the Confidential Information of the disclosing Party, as evidenced
by the receiving Party’s written records. 
 6.2    Permitted Disclosures.
Subject to the prior written consent of the other Party, which consent will not be unreasonably withheld or delayed, each Party may disclose the other’s Confidential Information to the extent such disclosure is reasonably necessary in filing or
prosecuting patent applications, prosecuting or defending litigation, advising investors and the investment community of the results of the activities under this Agreement , complying with applicable governmental regulations or court orders, or
otherwise in performing its obligations or exercising its rights under this Agreement. If a Party is required to make any such disclosure of the other Party’s Confidential Information, it will give reasonable advance notice to that other Party
of such disclosure requirement, will cooperate with the other Party in its efforts to secure confidential treatment of such Confidential Information prior to its disclosure, and, except to the extent inappropriate in the case of patent applications,
will use all reasonable efforts to secure confidential treatment of such information prior to its disclosure (whether through protective orders or confidentiality agreements or otherwise). 

  
 15 

  

6.3    Disclosure of Agreement Terms. Except to the extent required by law or as otherwise
permitted in accordance with this Section 6.3, neither Party shall make any public announcements concerning this Agreement or publish its terms without the prior written consent of the other Party. Notwithstanding the foregoing, either Party
shall have the right to disclose this Agreement or its terms to the extent disclosure is required under applicable law, regulation, or valid order of a court or other governmental body to which such Party is subject, provided that such Party shall
in good faith seek to minimize the extent of such disclosure through a protective order or confidential treatment order and, provided further, that such Party shall, as soon as practicable after becoming aware of the need for such disclosure, give
written notice to the other Party of the need for such disclosure so that such other Party may (if it elects and at its own cost) also seek a protective order or other confidential treatment. 

ARTICLE 7 

REPRESENTATIONS AND WARRANTIES 

7.1    Representations by Denka Seiken. Denka Seiken represents and warrants that as of the
Effective Date: (a) it is duly organized and validly existing under the laws of the jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement; (b) it has taken all corporate actions necessary
to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement; and (c) the performance of its obligations under this Agreement do not conflict with, or constitute a default under its
charter documents, any contractual obligation of Denka Seiken, or any court or administrative order. 

7.2    Representations by diaDexus. diaDexus represents and warrants that, as of the Effective
Date: (a) it is duly organized and validly existing under the laws of Delaware and has full corporate power and authority to enter into this Agreement; (b) it has taken all corporate actions necessary to authorize the execution and
delivery of this Agreement and the performance of its obligations under this Agreement; and (c) the performance of its obligations under this Agreement do not conflict with, or constitute a default under its charter documents, any contractual
obligation of diaDexus, or any court order. 
 7.3    Disclaimer of Warranties.
EXCEPT AS SPECIFICALLY SET FORTH IN THIS ARTICLE 7 OR SECTION 2.9, NO PARTY MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, NON-INFRINGEMENT, AND
ANY OTHER STATUTORY WARRANTY. 
 ARTICLE 8 
 INDEMNITY 

8.1    Indemnity by diaDexus. diaDexus hereby agrees to defend, indemnify, and hold Denka
Seiken, its employees, agents, and Affiliates harmless against any and all Third Party claims, liabilities, losses, damages, or expenses, (including, without limitation, attorney’s fees), to the extent resulting from, arising out of, or
connected with any inaccuracy, breach of, or nonfulfillment of any covenant, representation, warranty, or agreement made by or any other obligation of diaDexus contained in this Agreement. Notwithstanding the foregoing, neither Denka Seiken nor its
employees, agents, and Affiliates shall be entitled to indemnification for any claim, liability, loss, cost, damage, or expense to the extent caused by its or their own fraud, misrepresentation, negligence, or malfeasance. 

  
 16 

  

8.2    Indemnity by Denka Seiken. Denka Seiken hereby agrees to defend, indemnify, and hold
diaDexus, its employees, agents, and Affiliates harmless against any and all Third Party claims, liabilities, losses, damages, or expenses, (including, without limitation, attorney’s fees), to the extent resulting from, arising out of, or
connected with: (i) any inaccuracy, breach of, or nonfulfillment of any covenant, representation, warranty, or agreement made by or other obligation of Denka Seiken contained in this Agreement, or (ii) any products liability or negligence
claim arising from the Products produced under this Agreement. Neither diaDexus nor its employees, agents, and Affiliates shall be entitled to indemnification for any claim, liability, loss, cost, damage, or expense to the extent caused by its or
their own fraud, misrepresentation, negligence, or malfeasance. 
 8.3    Defense;
Settlement. The indemnified party shall give the indemnifying party reasonably prompt notice of any claims of Third Parties as to which it proposes to demand indemnification hereunder. The indemnifying party shall have the right to assume the
good faith defense, compromise, or settlement of any such claim (without prejudice to the right of the indemnified party to participate in such defense) at its own expense through attorneys reasonably acceptable to the indemnified party, but may
not, without the prior written consent of the indemnified party agree to (i) any injunctive relief or restrictions affecting the indemnified party or (ii) any settlement which would adversely affect the business or operations of the
indemnified party, including, without limitation, any admission of wrongdoing or fault by the indemnified party. If the indemnifying party does not elect to defend such claim or suit within ten (10) days after having received written notice
thereof or fails to prosecute its defense diligently, the indemnified party may at its sole discretion defend against such claim or suit at the indemnifying party’s expense. The indemnified party may thereafter elect to settle such claim or
suit or otherwise enter into a compromise with the claimant. 
 8.4    Damages;
Costs. If damages and/or costs are awarded against the indemnified party in any such claim or suit, whether or not Denka Seiken and/or diaDexus conduct the defense of such claim or suit, the indemnifying party shall indemnify and hold harmless
the indemnified party for all such damages and/or costs. All other costs and/or fees which result from the assertion of any such claim or suit, including but not limited to attorneys fees, incurred by the indemnified party in defense of any such
claim or suit shall be reimbursed to the indemnified party by the indemnifying party. 
 ARTICLE 9 

TERM AND TERMINATION 

9.1    Term. This Agreement will commence upon the Effective Date and, unless earlier
terminated pursuant to Sections 9.2 or 9.3, shall continue in effect until [*]                      (the “Term”). The Term of this
Agreement shall [*]
                                         unless a
Party gives written notice in accord with Section 10.6 prior to January 1 of the applicable year of expiration. 
  

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 17 

  

9.2    Termination for Cause. Either Party shall have the right to terminate this Agreement if
the other Party has materially breached the Agreement; provided, however, that such terminating Party shall notify the breaching Party in writing of such breach and, if such breach remains uncured thirty (30) days after the date such notice was
sent, the terminating Party shall have a right to terminate the Agreement immediately by sending a written termination notice to the breaching Party. 
 9.3    Consequences of Termination or Expiration. 
 (a)    Return of Materials. Upon termination or expiration of this Agreement each Party will promptly return all records and materials in its possession or control containing or
comprising the other Party’s know-how or other Confidential Information to which the former Party does not expressly retain rights under this Agreement. For the purpose of clarification, upon termination or expiration of this Agreement, Denka
Seiken shall return all Critical Components and ship all Products in its possession to diaDexus or diaDexus’ designee, or, at diaDexus’ discretion, shall destroy such Critical Components and/or Products and certify such destruction in
writing to diaDexus. 
 (b)    Accrued Liability. Termination or expiration of this
Agreement for any reason shall not release either Party from any liability which at the time of such termination or expiration has already accrued to the other Party prior to such time. Such termination or expiration will not relieve a Party from
accrued payment obligations or from obligations which are expressly indicated in this Agreement to survive termination or expiration of this Agreement. 
 (c)    Survival. The following Articles and Sections of this Agreement shall survive its termination or expiration: Articles 6, 8, and 10 and Sections 2.9, 4.2, 5.1, 7.3, and
9.3. 
 ARTICLE 10 
 GENERAL PROVISIONS 

10.1    Relationship of the Parties. The Parties are independent contractors. Nothing in this
Agreement is intended or will be deemed to constitute a partnership, agency, or employer-employee relationship between the Parties. Neither Party will incur any debts or make any commitments for the other Party. 

10.2    Assignments. Except as expressly provided herein, neither this Agreement nor any
interest under this Agreement will be assignable, nor any other obligation delegable, by a Party without the prior written consent of the other Party; provided, however, that diaDexus shall have the right to assign and otherwise transfer this
Agreement as a whole without consent to any successor that acquires all or substantially all of the business or assets of diaDexus by way of merger, consolidation, other business reorganization, or the sale of stock or assets, provided that diaDexus
notifies Denka Seiken in writing of such assignment, and such successor agrees in writing to be bound by the terms and conditions of this Agreement. This Agreement shall be binding upon successors and permitted assigns of diaDexus. Any assignment
not in accordance with this Section 10.2 will be null and void. 

  
 18 

  

10.3    Entire Agreement of the Parties; Amendments. This Agreement constitutes and contains
the entire understanding and agreement of the Parties respecting the subject matter of this Agreement and cancels and supersedes any and all prior and contemporaneous negotiations, correspondence, understandings, and agreements between the Parties,
whether oral or written, regarding such subject matter. No waiver, modification, or amendment of any provision of this Agreement will be valid or effective unless made in writing and signed by the Parties. 

10.4    Interpretation. The captions to this Agreement are for convenience only, and are to be
of no force or effect in construing or interpreting any of the provisions of this Agreement. All references in this Agreement to the singular shall include the plural where applicable, and all references to gender shall include both genders and the
neuter. Unless otherwise specified, references in this Agreement to any article shall include all sections, subsections, and paragraphs in such article; references in this Agreement to any section shall include all subsections and paragraphs in such
section; and references in this Agreement to any subsection shall include all paragraphs in such subsection. All references to days in this Agreement shall mean calendar days, unless otherwise specified. 

10.5    Governing Law; Dispute Resolution. 

(a)    If there arises, at any time during the Term, a dispute between the Parties relating to
any aspect of this Agreement or a Party’s performance hereunder, and such dispute is not resolved by informal discussion of the Parties within 15 business days after each Party is notified of such dispute, the dispute shall be immediately
referred to the CEO of diaDexus and General Manager of Int’l Sales and Business Development Department of Denka Seiken. Upon such referral, these two individuals shall immediately undertake good faith discussions, and shall be empowered to
reach a prompt, final resolution of the issue that shall be binding upon both Parties. If these two individuals do not resolve the dispute within 30 days after such referral, the matter will be resolved pursuant to the procedures described in
Sections 10.5(b)–(e). 
 (b)    The Parties agree that any discussion pursuant
to Section 10.5(a) will constitute settlement negotiations for purposes of the United States, federal and state rules of evidence and will be treated as non-discoverable, confidential and privileged communication by the Parties. No
stenographic, visual or audio record will be made of such discussions. 
 (c)    In
the event that any dispute with respect to the terms, conditions, construction or breach of this Agreement shall arise among the Parties, and such dispute shall not be resolved by the procedures described in Section 10.5(a), then, in that
event, either Party may notify the other Party that such dispute shall be submitted to arbitration by a panel of three arbitrators in San Francisco County, California, or such at other place as the Parties may mutually agree. The jurisdiction of the
arbitrators shall be exclusive, except as shall be expressly provided otherwise in this Agreement. Both Parties consent to the jurisdiction and venue of the arbitration panel in San Francisco County, California. The arbitrators shall conduct their
proceedings in English in accordance with the Commercial Arbitration Rules of the American Arbitration Association, or such other rules with respect to fees, procedural and other matters as the Parties or the arbitrators shall agree. 

  
 19 

  

(d)    Within 30 days after a notice for arbitration given by either Party in accordance with
in Section 10.5(c), each Party shall give written notice to the other Party of their choice of an independent arbitrator. Such person need not be an attorney. Within 30 days thereafter, the two arbitrators so chosen shall determine a third
arbitrator who shall act as chairman of the arbitration panel. The arbitrators shall be qualified, neutral, disinterested, unbiased and independent of the Parties and others having any known interest in the outcome, shall abide by the American Bar
Association and AAA Code of Ethics for neutral arbitrators. The arbitrators shall render a decision within 60 days of appointment. Any award rendered by the arbitrators shall be final, conclusive and binding on the Parties and there shall be no
right of appeal therefrom. Judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof, and both Parties consent to the non-exclusive jurisdiction of the United States District Court for the Northern
District of California for the purpose of enforcing any award of the arbitrators. All costs of the proceeding, including attorney’s fees, shall be paid by the non-prevailing Party, or as otherwise agreed to by the Parties. 

(e)    This Agreement will be governed by and interpreted in accordance with the laws of the
State of California, applicable to contracts entered into and to be performed wholly within the State of California, excluding conflict of laws principles that would result in the application of the laws of any jurisdiction other than the State of
California. 
 10.6    Notices and Deliveries. Any notice, request, delivery,
approval, or consent required or permitted to be given under this Agreement will be in writing and will be deemed to have been sufficiently given if delivered in person, transmitted by telecopier (receipt verified) or by express courier service
(signature required) or five (5) days after it was sent by registered letter, return receipt requested (or its equivalent), provided that no postal strike or other disruption is then in effect or comes into effect within two (2) days after
such mailing, to the Party to which it is directed at its address or facsimile number shown below or such other address or facsimile number as such Party will have last given by notice to the other Party. 

If to Denka Seiken, addressed to: 

Denka Seiken 

3-4-2 Nihonbashi Kayabacho 

Chuo-ku, Tokyo 103-0025, Japan 

Attn.: General Manager of Int’l Sales and Business Development 

Fax:    +81-3-3669-9390 

  
 20 

  
 If to
diaDexus, addressed to: 
 diaDexus, Inc. 

343 Oyster Point Boulevard 

South San Francisco, California 94080 

United States of America 

Attn.: Chief Executive Officer 

Fax: (650) 246-6499 

10.7    Limitation of Liability. EXCEPT WITH RESPECT TO UNAUTHORIZED EXPLOITATION OF THE OTHER
PARTY’S INTELLECTUAL PROPERTY RIGHTS OR BREACH OF THE CONFIDENTIALITY OR INDEMNITY OBLIGATIONS UNDER THIS AGREEMENT, IN NO EVENT WILL ANY PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE TO THE ANY OTHER PARTY OR ANY OF ITS AFFILIATES FOR
SPECIAL, INDIRECT, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY, OR OTHERWISE, INCLUDING BUT NOT LIMITED TO, LOSS OF PROFITS OR REVENUE OR CLAIMS OF CUSTOMERS OF ANY OF
THEM OR OTHER THIRD PARTIES FOR SUCH DAMAGES. 
 10.8    Force Majeure. No delay or
failure in performance by a Party under this Agreement shall be considered a breach of this Agreement if and to the extent caused by occurrences beyond the reasonable control of the Party affected and without such Party’s fault or negligence,
including but not limited to acts of God, embargoes, governmental restrictions, strikes or other concerted acts of workers, fire, earthquake, flood, tornadoes, explosion, riots, wars, civil disorder, acts of terrorism, rebellion, sabotage or other
causes; provided that the affected Party notifies the unaffected Party immediately as soon as reasonably possible and resumes performance hereunder as soon as reasonably possible following cessation of such force majeure event; and
provided further that no such delay or failure in performance shall continue for more than three (3) months. Any time for performance hereunder shall be extended by the actual time of delay caused by the occurrence, provided that
the Party affected by such event uses reasonable efforts to overcome such delay. In the event that a delay or failure in performance by a Party under this Section 10.8 continues longer than three (3) months, the other Party may terminate
this Agreement in accordance with the terms and conditions of Section 9.2. 

10.9    Waiver. A waiver by any Party of any of the terms and conditions of this Agreement in
any instance will not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach of this Agreement. All rights, remedies, undertakings, obligations, and agreements contained in this Agreement will be
cumulative and none of them will be in limitation of any other remedy, right, undertaking, obligation, or agreement of either Party. 
 10.10    Severability. If any provision of any provision of this Agreement shall be found by a court to be void, invalid, or unenforceable, the same shall be reformed to comply
with applicable law or stricken if not so conformable, so as not to affect the validity or enforceability of this Agreement; provided that no such reformation or striking shall be effective if the result materially changes the economic benefit of
this Agreement to either Party. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be void, invalid, or unenforceable, and reformation or striking of such provision would materially
change the economic benefit of this Agreement to either Party, the Parties shall modify such provision in accordance with Section 10.3 to obtain a legal, valid, and enforceable provision and provide an economic benefit to the Parties that most
nearly effects their intent on entering into this Agreement. 

  
 21 

  

10.11    Compliance with Laws. Notwithstanding anything to the contrary contained herein, all
rights and obligations of diaDexus and Denka Seiken are subject to prior compliance with, and each Party shall comply with, all U.S. and foreign export and import laws, regulations, and orders, and such other United States and foreign laws,
regulations, and orders as may be applicable, including obtaining all necessary approvals required by the applicable agencies of the governments of the United States and foreign jurisdictions. 

10.12    No Third Party Beneficiaries. This Agreement is neither expressly nor impliedly made
for the benefit of any party other than those executing it. 
 10.13    Counterparts.
This Agreement may be executed simultaneously in any number of counterparts, any one of which need not contain the signature of more than one Party but all such counterparts taken together will constitute one and the same agreement. 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be
executed by their respective duly authorized officers as of the Effective Date, each copy of which will for all purposes be deemed to be an original. 
 [Signature Page Follows] 

  
 22 

  

									
	DIADEXUS, INC.	 		 	DENKA SEIKEN
					
	By:	 	 /s/ Patrick Piewman
	 		 	By:	 	 /s/ Michio Ohtake

	Name:	 	 Patrick Piewman
	 		 	Name:	 	 Michio Ohtake

	 Title:
	 	 President & CEO
	 		 	 Title:
	 	 President

	Date:	 	 March 27, 2007
	 		 	Date:	 	 March 26, 2007

  
 23 

 EXHIBIT 1.6 

DENKA SEIKEN PATENT RIGHTS 
 [*] 
 Initials: diaDexus PP / Denka Seiken KM 

 
 [*] Certain information in this document has been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 E-1

  

EXHIBIT 1.5  
 CRITICAL COMPONENTS 
 [*] 

diaDexus PP / Denka Seiken KM 
  

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 E-2

  

EXHIBIT 1.8  
 DIADEXUS PATENT RIGHTS 
 [*] 

Initials: diaDexus PP / Denka Seiken KM 

 
 [*] Certain information in this document has been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 E-3

  

EXHIBIT 1.14  
 PRODUCTS 
 [*] 

Initials: diaDexus PP / Denka Seiken KM 

 
 [*] Certain information in this document has been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 E-4

  
 Initials: diaDexus
PP / Denka Seiken KM 

  
 E-5

  

EXHIBIT 1.16  
 SPECIFICATION 
  

			
	
Element
	  	Design inputs
	 [*]
	  	[*]

Initials: diaDexus PP / Denka Seiken KM 

 
 [*] Two pages have been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portion. 

  
 E-6

  

EXHIBIT 2.2 
 DEVELOPMENT PLAN AND TIMELINE 
 SEE
ATTACHED 
 Initials: diaDexus PP / Denka Seiken KM 

  
 E-8

  
 [*]

  
 [*] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

EXHIBIT 2.6  
 CRITICAL COMPONENTS SOP 
 [*] 

Initials: diaDexus PP / Denka Seiken KM 

 
 [*] Certain information in this document has been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 E-9

  

EXHIBIT 2.7 
 PURCHASE ORDER 
  

							
	
 

	  		  		  	
	 343 Oyster Point Boulevard
	  	 Phone

(650)246-6400
	  	 P.O.  
 Number  
	  	 

 

											
	
Supplier Name                     
                                      
	  		  	
	
Contact                       
                                         
       
	  	Phone                          
                                     	  	
	
Address                       
                                         
       
	  	Fax                          
                                         
 	  	
	
City                       
                               
	 	 State
	 	 	  	ZIP                          
                                         
 	  	

																																					
	Item
#	 	QTY	 	Units	 	Catalog
Number	 	Part No.
(GMP)	 	COA/COC
Required	 	Inspection
Required	 	Need
MSOS	 	Chemical / 
Reagent 	 	Lab
Supply	 	Other	  	Description	  	Unit
Price	 	  	Total
Cost	 	  	  
	 1
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	  	 	 	 	  	 	 	 	  	 	  	 	  	 
	 2
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	  	 	 	 	  	 	 	 	  	 	  	 	  	 
		 		 		 		 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	  	 
	Subtotal
	  
	  			 	  		  		  	
		 		 		 		 		 		 		 		 		 		 		  		  	  	 	 	 	  		  		  	
		 		 		 		 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	  	 
 	Sales
Tax	  
  	  			 	  		  		  	
		 		 		 		 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	  	  	 	 	 	  		  		  	
		 		 		 		 	  
 Facilities Manager
	 	 	 	 	 	 	 	 	 	 	  	 	  	   
	Freight  
	    
	  			 	  		  		  	
		 		 		 		 		 		 		 		 		 		 		  		  	  	 	 	 	  		  		  	
		 		 		 		 		 		 		 		 		 		 		  		  	 	Total	  	  	 	 	 	  		  		  	

  

											
	 Requested by  
	 	 	  	Date  	  	 	  		  	
						
	 Director/VP (> $10,000)  
	 	 	  	Date  	  	 	  	Date of Order  	  	 
						
	 CEO(> $20,000)  
	 	 	  	Date  	  	 	  	Ordered by  	  	 

 Initials: diaDexus
PP / Denka Seiken KM 

  
 E-10First Amendment to the Denka Seiken Agreement

  
 Exhibit 10.21

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 
 FIRST AMENDMENT TO 

DEVELOPMENT, MANUFACTURING, AND SUPPLY AGREEMENT 
 This first amendment (the “First Amendment”) to DEVELOPMENT, MANUFACTURING, AND SUPPLY AGREEMENT (the “Agreement”) is made effective as of July 21, 2008, 2008 (the “Amendment
Effective Date”) by and between DIADEXUS, INC., organized under the laws of Delaware and having its principal place of business at 343 Oyster Point Boulevard, South San Francisco, California 94080, United States of America
(“diaDexus”), and DENKA SEIKEN, organized under the laws of Japan and having its principal place of business at 3-4-2 Nihonbashi Kayabacho, Chuo-ku, Tokyo 103-0025, Japan (“Denka Seiken”). 

WITNESSETH: 
 WHEREAS, diaDexus and Denka Seiken entered into the DEVELOPMENT, MANUFACTURING, AND SUPPLY AGREEMENT (the “Agreement”) on March 27th, 2007; and 

WHEREAS, diaDexus and Denka Seiken desire to amend the Agreement as set forth below. 

NOW, THEREFORE, in consideration of the promises and undertakings set forth in this First Amendment, the Parties agree as follows:

  

	 	1.	Any capitalized terms used in this First Amendment, but not defined herein, shall have the meanings ascribed to them in the Agreement. 

 

	 	2.	Exhibit 1.14 shall be replaced with Exhibit 1.14.2 attached to this First Amendment. 

 

	 	3.	Exhibit 1.16 shall be replaced with Exhibit 1.16.2 attached to this First Amendment. 

 

	 	4.	 diaDexus is released from its obligations for the milestone payments stipulated in Section 3.2 (a) and also from some parts of the
milestone payments stipulated in Section 3.2 (b) as detailed below. Instead diaDexus agrees to pay the total amount shown in the table in Article 6 as a part of the Transfer Price for the 1st commercial lot of the Product. 

  
 [*] 

 

	 	5.	 diaDexus agrees to pay for the validation lots of the Products manufactured by Denka Seiken according to the Transfer Price stipulated in
Section 3.3. With an assumption that total number of tests to be shipped in the 1st Fiscal Year [*]. The quantities and costs of the validation lots are summarized below. diaDexus agrees to pay the total amount shown in the table in Article 6 as a part of the Transfer Price for the
1st commercial lot of the Product. Denka Seiken agrees to
pay for the rare reagents to diaDexus for those used for the validation lots shown in the following table. 

[*] 
 [*] Certain information in
this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

	 	6.	In consideration of Article 4 and Article 5 above, the Transfer Price for the 1st commercial lot of the Product are determined as shown below. These prices are applied
one time only and only for the 1st commercial lot to be released [*]. 

 [*] 

 

	 	7.	Continuance of Exhibit; Single Document. Except as specifically amended by this Amendment, all provisions in the Agreement shall remain in full force and effect. The
Agreement, as amended by this Amendment, should hereafter be read as a single integrated document, incorporating the changes set forth in this Amendment. 

 IN WITNESS WHEREOF, diaDexus and DENKA SEIKEN have this Amendment to be executed by their respective duly authorized officers as of the date first above written. 

 

									
	DIADEXUS INC.	 		  	DENKA SEIKEN
					
	By:	  	 /s/ P. Plewman
	 		  	By:	  	 /s/ Hiroshi Adachi

	Name:	  	 P. Plewman
	 		  	Name:	  	 Hiroshi Adachi

	Title:	  	 President & CEO
	 		  	Title:	  	 Senior General Manager

	Date:	  	 Jul 21, 2008
	 		  	Date:	  	 July 3, 2008

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

  
 EXHIBIT 1.14.2

 PRODUCTS 
 [*] 
 [*] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 EXHIBIT 1.16.2

 SPECIFICATION 
  

			
	 Element
	  	 Design Inputs

	    [*]	  	[*]

  

			
	[*] Three pages have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portion.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]